472 related articles for article (PubMed ID: 34209213)
1. Emerging Evidence for Pleiotropism of Eosinophils.
Rodrigo-Muñoz JM; Gil-Martínez M; Sastre B; Del Pozo V
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209213
[TBL] [Abstract][Full Text] [Related]
2. Eosinophils in mucosal immune responses.
Travers J; Rothenberg ME
Mucosal Immunol; 2015 May; 8(3):464-75. PubMed ID: 25807184
[TBL] [Abstract][Full Text] [Related]
3. Targeting granulocyte-macrophage colony-stimulating factor in epithelial and vascular remodeling in experimental eosinophilic esophagitis.
McNamee EN; Biette KA; Hammer J; Harris R; Miyazawa H; Lee JJ; Furuta GT; Masterson JC
Allergy; 2017 Aug; 72(8):1232-1242. PubMed ID: 27926989
[TBL] [Abstract][Full Text] [Related]
4. The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review.
Eng SS; DeFelice ML
Clin Rev Allergy Immunol; 2016 Apr; 50(2):140-58. PubMed ID: 26797962
[TBL] [Abstract][Full Text] [Related]
5. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
6. Eosinophil Response Against Classical and Emerging Respiratory Viruses: COVID-19.
Rodrigo-Muñoz JM; Sastre B; Cañas JA; Gil-Martínez M; Redondo N; Del Pozo V
J Investig Allergol Clin Immunol; 2021 Apr; 31(2):94-107. PubMed ID: 32540792
[TBL] [Abstract][Full Text] [Related]
7. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
8. Advances in eosinophilic diseases in 2018.
Klion AD; Rothenberg ME
J Allergy Clin Immunol; 2019 Dec; 144(6):1490-1494. PubMed ID: 31655098
[TBL] [Abstract][Full Text] [Related]
9. Active eosinophilic esophagitis is characterized by epithelial barrier defects and eosinophil extracellular trap formation.
Simon D; Radonjic-Hösli S; Straumann A; Yousefi S; Simon HU
Allergy; 2015 Apr; 70(4):443-52. PubMed ID: 25620273
[TBL] [Abstract][Full Text] [Related]
10. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
[TBL] [Abstract][Full Text] [Related]
11. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases.
Schmid-Grendelmeier P; Altznauer F; Fischer B; Bizer C; Straumann A; Menz G; Blaser K; Wüthrich B; Simon HU
J Immunol; 2002 Jul; 169(2):1021-7. PubMed ID: 12097410
[TBL] [Abstract][Full Text] [Related]
12. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.
Menzies-Gow A; Flood-Page P; Sehmi R; Burman J; Hamid Q; Robinson DS; Kay AB; Denburg J
J Allergy Clin Immunol; 2003 Apr; 111(4):714-9. PubMed ID: 12704348
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
[TBL] [Abstract][Full Text] [Related]
15. Eosinophils as Major Player in Type 2 Inflammation: Autoimmunity and Beyond.
Folci M; Ramponi G; Arcari I; Zumbo A; Brunetta E
Adv Exp Med Biol; 2021; 1347():197-219. PubMed ID: 34031864
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
17. Delayed eosinophil apoptosis in asthma.
Kankaanranta H; Lindsay MA; Giembycz MA; Zhang X; Moilanen E; Barnes PJ
J Allergy Clin Immunol; 2000 Jul; 106(1 Pt 1):77-83. PubMed ID: 10887309
[TBL] [Abstract][Full Text] [Related]
18. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
19. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
Varricchi G; Bagnasco D; Ferrando M; Puggioni F; Passalacqua G; Canonica GW
Ther Adv Respir Dis; 2017 Jan; 11(1):40-45. PubMed ID: 27856823
[TBL] [Abstract][Full Text] [Related]
20. Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview.
Hassani M; Koenderman L
Allergy; 2018 Oct; 73(10):1979-1988. PubMed ID: 29611207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
